BC Innovations | Jul 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting DPP-8 and DPP-9 could help treat AML. In 12 human AML cell lines, the DPP-8/DPP-9 inhibitor BXCL701 or two tool compound dual DPP-8/DPP-9...
BC Week In Review | Mar 16, 2018
Financial News

AI play BioXcel raises $60M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO and Canaccord Genuity. The...
BC Extra | Mar 8, 2018
Financial News

AI play BioXcel raises $60M IPO

BioXcel Therapeutics Inc. (NASDAQ:BTAI) gained $0.03 to $11.03 Thursday after the artificial intelligence company raised $60 million through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO...
BC Week In Review | May 19, 2017
Company News

BioXcel creates subsidiary to develop cancer, neurology candidates

BioXcel Corp. (Branford, Conn.) launched new subsidiary BioXCel Therapeutics Inc. (BTI), which will use artificial intelligence-driven R&D to identify indications for candidates that demonstrated safety but not efficacy in Phase II testing or later. BTI's...
BC Innovations | Oct 2, 2008
Cover Story

Truly Boronic

Researchers at Tufts University have shown that peptide boronic acid inhibitors of dipeptidyl peptidase-4 could provide effective, low-toxicity treatments for diabetes. 1 The findings challenge the long-held assumption that boronic acids are too toxic for...
BC Innovations | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes Dipeptidyl peptidase-4 (DPP-4); DPP-8; DPP-9 Studies in rodents and in human cells suggest that DPP-4-specific, dipeptide...
BC Innovations | Jan 31, 2008
Cover Story

CD200: A Solid Argument

The two companies developing anti- CD200 antibodies to treat blood cancers- Alexion Pharmaceuticals Inc. and Trillium Therapeutics Inc .-might have had a new indication land in their laps. In a paper published in The Journal...
BC Week In Review | Oct 15, 2007
Company News

Dara BioSciences, Point Therapeutics, Bayer deal

Dara and POTP will reverse-merge. Dara stockholders will own 96.4% of the combined company, and POTP shareholders will own the remaining 3.6%. Dara's lead compound is KRN5500 , a spicamycin derivative licensed from Kirin Brewery Co....
BioCentury | Oct 15, 2007
Finance

Ebb & Flow

Profit-taking by investors after its IPO lock-up expired may have been behind last week's share price dip for cancer and autoimmune company Synta (SNTA), which shed $2.24 (20%) to $8.76 despite announcing a potentially blockbuster...
BC Extra | Oct 10, 2007
Company News

Dara, Point Therapeutics to reverse merge

Dara (Raleigh, N.C.) and POTP will reverse merge to create Dara BioSciences Inc. Dara stockholders will own 96.4% of the combined company and POTP shareholders will own the remaining 3.6%. Dara's lead compound is KRN5500...
Items per page:
1 - 10 of 26